Literature DB >> 352513

Progress and controversy in the treatment of childhood rhabdomyosarcoma.

D M Green, N Jaffe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 352513     DOI： 10.1016/s0305-7372(78)80003-6

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  5 in total

Review 1.  Current impact of adjuvant chemotherapy in resectable cancer.

Authors:  A Rossi; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  [Therapy of malignant soft tissue tumors in children (authors' transl)].

Authors:  G Schellong
Journal:  Langenbecks Arch Chir       Date:  1981

4.  Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.

Authors:  P J Houghton; J A Houghton; L Myers; P Cheshire; J J Howbert; G B Grindey
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Surgical Principles for Children/Adolescents With Newly Diagnosed Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David A Rodeberg; Charles N Paidas; Thom L Lobe; Kenneth Brown; Richard J Andrassy; William M Crist; Eugene S Wiener
Journal:  Sarcoma       Date:  2002
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.